Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice.

Publication

Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice.

Journal Paper/Review - Feb 7, 2023

Paolucci Marta, Wuillemin Natascha, Homère Valentine, Bieli Dimitri, Köhli Alice, Ballmer-Weber Barbara, Waeckerle-Men Ying, Pengo Niccolò, Kündig Thomas M, Sonati Tiziana, Johansen Pål

Citation

Paolucci M, Wuillemin N, Homère V, Bieli D, Köhli A, Ballmer-Weber B, Waeckerle-Men Y, Pengo N, Kündig T, Sonati T, Johansen P. Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice. Allergy 2023; 78:1605-1614.

Type

Journal Paper/Review (English)

Journal

Allergy 2023; 78

Publication Date

Feb 7, 2023

Issn Electronic

1398-9995

Pages

1605-1614

Brief description/objective

Peanut allergy is a type-I hypersensitivity immune reaction mediated by the binding of peanut allergens to IgE-FcεRI complexes on mast cells and basophils and by their subsequent cellular degranulation. Of all major peanut allergens, Ara h 2 is considered the most anaphylactic. With few options but allergen avoidance, effective treatment of allergic patients is needed. Passive immunotherapy (herein called PIT) based on prophylactic administration of peanut-specific monoclonal antibodies (mAbs) may present a promising treatment option for this under-served disease.